Stellate Ganglion Block for the Management of Cannabis Use Disorder: A Case Series
N Charan1, Varsha Karanth2, Shruti Niraj3
1Pain Medicine and Palliative Care, Sri Madhusudan Sai Institute of Medical Sciences & Research, Chikkaballapur, IND.
Abstract:
Currently, there are no approved or consistently effective pharmacological treatments for managing cannabis use disorder. Three patients diagnosed with cannabis use disorder and presenting with cannabis withdrawal syndrome were assessed by an interdisciplinary team. These patients were treated with two-level dual stellate ganglion blocks. Validated patient-reported outcome measures were completed. Urine cannabis levels were measured at the four-week follow-up. At one-, two-, and four-week reviews, all three patients reported reduced withdrawal symptoms. Urine cannabis tests were negative at the four-week review. Limitations include a small cohort of patients, absence of a control arm, and possible placebo effects. Stellate ganglion block could have a role in the management of cannabis use disorder and cannabis withdrawal syndrome.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Drugs Acting on Autonomic Ganglia: Blockers
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Chronic Pancreatitis II: Collaborative Care
Assessment:


